Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-celloriginated protein kinase

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: LI, Hua (Wuhan, China)
  • Co-author(s): Mengzhu Zheng: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Suyu Gao: Wuya College of Innovation,School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China
    Shanshan Luan : School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Lixia Chen: Wuya College of Innovation,School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China
    Hua Li: School of Pharmacy, Tongji Medical College , Huazhong University of Science and Technology, Wuhan, China
  • Abstract:

    Backgrounds

    T-cell-originated protein kinase (TOPK) is highly expressed in several cancer cells and promotes tumorigenesis and progression, and therefore, it is an important target for drug treatment of tumor.

    Aims

     Discovery of a TOPK selective inhibitor which can suppress the growth of cancer cells.

    Methods

    A series of methods were used, including in

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses